Skip to main content
Premium Trial:

Request an Annual Quote

FDA Approves Thermo Fisher HLA Typing Test as CDx for Immunocore Uveal Melanoma Therapy

NEW YORK – Thermo Fisher Scientific said on Wednesday that its SeCore CDx HLA Sequencing System was granted de novo classification by the US Food and Drug Administration as a companion diagnostic to Immunocore’s Kimmtrak (tebentafusp-tebn) therapy for uveal melanoma.

Kimmtrak is the only T-cell receptor therapy approved by the FDA for metastatic or unresectable uveal melanoma, a rare but deadly eye cancer, and is indicated for adults who are human leukocyte antigen (HLA)-A*02:01 positive. The marketing authorization makes the SeCore CDx HLA Sequencing System the first and so far only commercially available HLA typing companion diagnostic, Thermo Fisher said.

“Clinicians can now use the SeCore CDx HLA Sequencing System to identify individuals who may benefit from this breakthrough immunotherapy,” Nicole Brockway, Thermo Fisher’s president of transplant diagnostics, said in a statement. “We look forward to continuing to partner with leading-edge companies to develop and commercialize immunotherapies that address unmet needs in a variety of disease areas.”

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.